公开(公告)号：US20170251715A1

公开(公告)日：2017-09-07

申请号：US15062907

申请日：2016-03-07

Applicant: R.J. REYNOLDS TOBACCO COMPANY

Inventor： Serban C. Moldoveanu ,  Wayne Allen Scott

IPC: A24B15/30 ,  A24B15/34 ,  A61K36/53 ,  A24B13/00 ,  A61K9/00 ,  A61K31/56

CPC classification number: A24B15/302 ,  A24B13/00 ,  A24B15/345 ,  A61K9/007 ,  A61K31/56 ,  A61K36/53 ,  A61K36/81 ,  A61K2300/00

Abstract: Provided are smoking products and methods of preparing smoking products that include tobacco and a deflavored rosemary or a heat-treated rosemary. The deflavored and/or heat-treated rosemary may have been previously heated at a temperature and a time sufficient to reduce or remove flavorant components compared to the use of untreated rosemary. The heated rosemary may include one or more pentacyclic triterpenoid acids such as betulinic, betul-18-enoic, oleanolic, and ursolic acids.

公开(公告)号：US20170239269A1

公开(公告)日：2017-08-24

申请号：US15519460

申请日：2015-10-16

Applicant: Teva Branded Pharmaceutical Products R&D, Inc.

Inventor： Mukul Dalvi ,  Jacquelyn McCabe

IPC: A61K31/56 ,  A61K9/12 ,  A61K9/00

CPC classification number: A61K31/56 ,  A61K9/0075 ,  A61K9/008 ,  A61K9/124

Abstract: This invention provides a process for preparing an inhalable active pharmaceutical ingredient comprising the steps of heating a suspension of an active pharmaceutical ingredient in a liquefied propellant in a vessel, evaporating the propellant and collecting the resultant powder.

公开(公告)号：US20170231967A1

公开(公告)日：2017-08-17

申请号：US15584459

申请日：2017-05-02

Applicant: vTv Therapeutics LLC

Inventor： Otis Clinton Attucks

IPC: A61K31/437 ,  A61K31/56 ,  A61K31/428

CPC classification number: A61K31/437 ,  A61K31/428 ,  A61K31/56 ,  Y02A50/395

Abstract: The disclosure provides pharmaceutical compositions comprising Bach1 Inhibitors and Nrf2 Activators. The disclosure also provides methods of treating diseases such as psoriasis, multiple sclerosis, and COPD comprising administering a Bach1 Inhibitor and a Nrf2 Activator to a subject in need thereof.

公开(公告)号：US09717743B2

公开(公告)日：2017-08-01

申请号：US14485335

申请日：2014-09-12

Applicant: Allergan, Inc.

Inventor： Jeffrey L. Edelman ,  Alissar Nehme

IPC: A61K31/56 ,  A61K31/575 ,  A61K31/58 ,  C07J7/00 ,  C07J17/00 ,  C07J31/00 ,  A61K9/00 ,  A61K31/573 ,  C07J5/00

CPC classification number: A61K31/58 ,  A61K9/0048 ,  A61K31/56 ,  A61K31/573 ,  A61K31/575 ,  A61K2121/00 ,  C07J5/0053 ,  C07J7/008 ,  C07J17/00 ,  C07J31/006

Abstract: The present invention relates to pharmaceutical compositions comprising 4-pregenen-11β-17-21-triol-3,20-dione derivatives, and their use as pharmaceuticals as modulators of the glucocorticoid receptors (GR) and/or the mineralocorticoid receptors (MR). The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat ocular conditions associated with the glucocorticoid receptors (GR) and/or the mineralocorticoid receptors (MR).

公开(公告)号：US20170196985A1

公开(公告)日：2017-07-13

申请号：US15316742

申请日：2015-06-05

Applicant: THE SCRIPPS RESEARCH INSTITUTE

Inventor： Jiajia DONG ,  K. Barry SHARPLESS ,  Jeffery W. KELLY ,  Aleksandra BARANCZAK ,  Wentao CHEN

IPC: A61K47/48 ,  C07K1/02 ,  C07K2/00 ,  A61K31/56 ,  A61K31/5513 ,  A61K31/515 ,  A61K31/485 ,  A61K31/4353 ,  A61K31/65 ,  A61K31/7048 ,  A61K31/70 ,  A61K31/05 ,  A61K31/655 ,  A61K31/4245 ,  A61K31/407 ,  A61K31/4168 ,  A61K31/40 ,  A61K31/505 ,  A61K31/14 ,  A61K31/473 ,  A61K31/53 ,  A61K31/197 ,  A61K31/4745 ,  A61K31/47 ,  A61K31/397 ,  A61K31/198 ,  A61K38/31 ,  A61K31/439 ,  A61K31/4045 ,  A61K51/04 ,  A61K31/136 ,  A61K31/4709 ,  C07C305/26 ,  C07K1/113 ,  C07K19/00

CPC classification number: A61K31/05 ,  A61K31/136 ,  A61K31/14 ,  A61K31/197 ,  A61K31/198 ,  A61K31/397 ,  A61K31/40 ,  A61K31/4045 ,  A61K31/407 ,  A61K31/4168 ,  A61K31/4245 ,  A61K31/4353 ,  A61K31/439 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/473 ,  A61K31/4745 ,  A61K31/485 ,  A61K31/505 ,  A61K31/515 ,  A61K31/53 ,  A61K31/5513 ,  A61K31/56 ,  A61K31/65 ,  A61K31/655 ,  A61K31/70 ,  A61K31/7048 ,  A61K38/31 ,  A61K47/54 ,  A61K51/0497 ,  C07C305/26 ,  C07C2601/14 ,  C07C2603/18 ,  C07D277/82 ,  C07D295/088 ,  C07D295/185 ,  C07D295/26 ,  C07K1/02 ,  C07K1/1136 ,  C07K2/00

Abstract: This application describes a compound represented by Formula (I): (I) wherein: Y is a biologically active organic core group comprising one or more of an aryl group, a heteroaryl aryl group, a nonaromatic hydrocarbyl group, and a nonaromatic heterocyclic group, to which Z is covalently bonded; n is 1, 2, 3, 4 or 5; m is 1 or 2; Z is O, NR, or N; X1 is a covalent bond or —CH2CH2—, X2 is O or NR; and R comprises H or a substituted or unsubstituted group selected from an aryl group, a heteroaryl aryl group, a nonaromatic hydrocarbyl group, and a nonaromatic heterocyclic group. Methods of preparing the compounds, methods of using the compounds, and pharmaceutical compositions comprising the compounds are described as well.

公开(公告)号：US20170196935A1

公开(公告)日：2017-07-13

申请号：US15241895

申请日：2016-08-19

Applicant: CSL Limited

Inventor： Samuel Wright ,  Martin Imboden ,  Reinhard Bolli ,  Marcel Waelchli

IPC: A61K38/17 ,  A61K31/575 ,  A61K31/685

CPC classification number: A61K38/1709 ,  A61K9/0019 ,  A61K9/1275 ,  A61K31/56 ,  A61K31/575 ,  A61K31/685 ,  A61K45/06 ,  A61K2300/00

Abstract: A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAI or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/L and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75. The formulation is useful for treating diseases or conditions such as cardiovascular disease, hypercholesterolaemia and hypocholesterolaemia inclusive of acute coronary syndrome (ACS), atherosclerosis and myocardial infarction.

公开(公告)号：US20170196823A1

公开(公告)日：2017-07-13

申请号：US14990168

申请日：2016-01-07

Applicant: CMPD LICENSING, LLC

Inventor： Jay Richard Ray, III

IPC: A61K31/17 ,  A61K31/496 ,  A61K47/10 ,  A61K9/06 ,  A61K9/00 ,  A61K31/56 ,  A61K31/351

CPC classification number: A61K31/17 ,  A61K9/0014 ,  A61K9/06 ,  A61K31/351 ,  A61K31/496 ,  A61K31/56 ,  A61K47/10 ,  A61K2300/00

Abstract: A topical cream may include urea and one or more additional active agents such as fluticasone, itraconazole, and mupirocin. The topical cream may be formulated as a lotion, gel, ointment, foam, cream, or emulsion

公开(公告)号：US20170188902A1

公开(公告)日：2017-07-06

申请号：US15394650

申请日：2016-12-29

Applicant: DexCom, Inc.

Inventor： Shanger Wang ,  Ted Tang Lee ,  Jiong Zou

IPC: A61B5/1473 ,  C12Q1/00 ,  A61B5/145 ,  C12N11/08

CPC classification number: G01N27/3273 ,  A61B5/0004 ,  A61B5/002 ,  A61B5/14532 ,  A61B5/14546 ,  A61B5/1473 ,  A61B5/1486 ,  A61B5/14865 ,  A61B2562/12 ,  A61K31/045 ,  A61K31/137 ,  A61K31/46 ,  A61K31/465 ,  A61K31/485 ,  A61K31/515 ,  A61K31/56 ,  A61K33/00 ,  A61K36/185 ,  A61K38/28 ,  C08G18/0828 ,  C08G18/12 ,  C08G18/3857 ,  C08G18/4018 ,  C08G18/44 ,  C08G18/4833 ,  C08G18/755 ,  C08L39/06 ,  C08L69/00 ,  C08L75/04 ,  C12N11/08 ,  C12Q1/002 ,  C12Q1/006 ,  G01N27/3275 ,  G01N33/66 ,  C08G18/3234

Abstract: Disclosed are devices for determining an analyte concentration (e.g., glucose). The devices comprise a sensor configured to generate a signal associated with a concentration of an analyte and a sensing membrane located over the sensor. The sensing membrane comprises an enzyme layer, wherein the enzyme layer comprises an enzyme and a polymer comprising polyurethane and/or polyurea segments and one or more zwitterionic repeating units. The enzyme layer protects the enzyme and prevents it from leaching from the sensing membrane into a host or deactivating.

公开(公告)号：US20170173048A1

公开(公告)日：2017-06-22

申请号：US15129539

申请日：2015-03-30

Applicant: Vesna Jevtovic-Todorovic ,  Slobodan Todorovic

Inventor： Vesna Jevtovic-Todorovic ,  Slobodan Todorovic

IPC: A61K31/568

CPC classification number: A61K31/568 ,  A61K31/56 ,  A61K31/565 ,  A61K31/58

Abstract: The present application discloses the unexpected result that a neuroactive steroid such as B260 can act as a general anesthetic and that it has no neurotoxic side effects such as impairing brain development.

公开(公告)号：US20170172925A1

公开(公告)日：2017-06-22

申请号：US15453940

申请日：2017-03-09

Applicant: Norton Healthcare Ltd.

Inventor： Xian-Ming ZENG ,  Seah Kee TEE

IPC: A61K9/16 ,  A61K31/56 ,  A61K31/167 ,  A61K9/00 ,  A61K31/58

CPC classification number: A61K9/1623 ,  A61K9/0075 ,  A61K9/1694 ,  A61K31/137 ,  A61K31/167 ,  A61K31/56 ,  A61K31/58

Abstract: The present invention provides a process for preparing a particulate medicament that has greater homogeneity and a lower adhesion between the particles of the active ingredient and the carrier. The process comprises the steps of: (a) combining a pharmaceutically active ingredient in the form of an agglomerate of primary particles having an agglomerate particle size such that the agglomerate is capable of passing through a sieve having a mesh of 50-3000 .mu·m with a pharmaceutically acceptable particulate carrier, and (b) mixing the resultant material in a mixer to break up the agglomerate into primary particles dispersed in the pharmaceutically acceptable particulate carrier such that 90% or more of the pharmaceutically active ingredient exists as primary particles having a particle size of 50 .mu·m or less.